Q-omics provides the consensus-scored IL1RN profile across patient tissues and cancer cell-line models. IL1RN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL1RN is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, IL1RN protein abundance shows 24,555 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where IL1RN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL1RN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL1RN survival associations across molecular data types. IL1RN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL1RN RNA expression–survival associations across cancer types. High IL1RN expression shows unfavorable associations in KIRC, UVM, SCLC, KIRP, PAAD and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL1RN RNA expression.
This table summarizes IL1RN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL1RN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL1RN shows lower tumor expression in LIHC, KICH and CHOL and higher tumor expression in COAD, THCA and UCEC. The COAD box plot shows higher IL1RN RNA expression in tumor versus normal tissue (log2 FC = +1.923, t-test p < 0.001).
This table shows molecular features associated with IL1RN in patient tissues and cancer cell lines. In patient samples, IL1RN shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL1RN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
